Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB Trial of tozorakimab in COPD
NL-OMON61768Phase 2Withdrawn
- Sponsor
- University of Leicester
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by University of Leicester. Primary endpoints: Improvement in epithelial remodelling histology score and Improvement in bronchial submucosal granulocytic inflammation. Planned start Oct 2026; status: withdrawn.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON61768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61768.